Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Operating Expenses (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Other Operating Expenses readings, the most recent being $29.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses fell 27.26% year-over-year to $29.7 million, compared with a TTM value of $102.2 million through Dec 2025, down 13.15%, and an annual FY2025 reading of $102.2 million, down 13.16% over the prior year.
  • Other Operating Expenses hit $29.7 million in Q4 2025 for Apellis Pharmaceuticals, up from $24.5 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $50.0 million in Q2 2021, with the low at $82000.0 in Q2 2022.
  • Median Other Operating Expenses over the past 5 years was $20.2 million (2024), compared with a mean of $19.2 million.
  • The sharpest move saw Other Operating Expenses tumbled 99.84% in 2022, then skyrocketed 10118.29% in 2023.
  • Year by year, Other Operating Expenses stood at $30.1 million in 2021, then crashed by 90.27% to $2.9 million in 2022, then skyrocketed by 580.75% to $19.9 million in 2023, then soared by 105.18% to $40.9 million in 2024, then dropped by 27.26% to $29.7 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $29.7 million, $24.5 million, and $13.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.